Journal
JOURNAL OF NEUROLOGY
Volume 269, Issue 1, Pages 39-43Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-021-10663-x
Keywords
Multiple sclerosis; COVID-19; SARS-CoV-2 vaccination; Fingolimod; Ocrelizumab
Categories
Ask authors/readers for more resources
This study found variable antibody production in multiple sclerosis patients receiving fingolimod or ocrelizumab treatments after receiving a complete SARS-CoV-2 vaccination course. Clinical features did not show a clear correlation with serological response. There is currently insufficient data to recommend against COVID-19 vaccination in these patients.
Background Recent observations suggest a lack of humoral response after SARS-CoV-2 vaccination in multiple sclerosis (MS) patients treated with fingolimod or ocrelizumab Objectives To assess serological response to SARS-CoV-2 vaccination in MS patients receiving these disease-modifying treatments (DMTs) in a real-life setting. Methods Retrospective clinical data collection from MS patients followed at San Raffaele Hospital MS Centre (Milan, Italy). All patients treated with fingolimod or ocrelizumab who had received a complete anti-COVID-19 vaccination course, with no clinical history suggestive of previous SARS-CoV-2 infection and with an available post-vaccination serological assay obtained at least 14 days after vaccination completion were considered for the study. Results We collected data from 32 MS patients, 16 treated with fingolimod and 16 receiving ocrelizumab. Among the fingolimod group 10 patients (62.5%) had a positive serological response after vaccination and among ocrelizumab-treated patients a positive serological test was found in six cases (37.5%). No relation between serological response and clinical features (i.e., treatment duration, time between vaccination and last treatment dose, and white blood cells count) was identified. Conclusions Our initial real-life experience suggests a variable antibody production in MS patients receiving these DMTs. At present, there are no sufficient data to do not recommend anti-SARS-CoV-2 vaccine in these patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available